The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves. Nektar Therapeutics NKTR slumped about 42 percent, while Deciphera Pharmaceuticals Inc DCPH has rallied about 60 percent since June 1.

Here's a look at the upcoming week's catalytic events.

Conferences

• 41st European Congress of Cytology – June 10-13, in Madrid, Spain
• 31st International Conference On Antiviral Research, or ICAR - June 11-15, in Porto, Portugal
• Goldman Sachs 39th Annual Global Healthcare Conference – June 12-14, in Rancho Palos Verdes, California
• Annual European Congress of Rheumatology, 2018 – June 13-16, in Amsterdam, Netherlands
• UK Oncology Forum – June 14-15, in Liverpool, U.K.
• 23rd Congress of European Hematology Association, or EHA, – June 14-17, in Stockholm, Sweden
• 52nd European Human Genetics Conference in conjunction with the European Meeting on Psychological Aspects of Genetics – June 16-19, in Milan, Italy

Related Link: Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Clinical Trial Presentations

Chimerix Inc CMRX is due to present Phase 1 data on its norovirus treatment candidate CMX521 at the ICAR between June 11-15. The company recently received orphan drug designation to its smallpox treatment candidate brincidofovir.

Beigene Ltd (ADR) BGNE will present Phase 1/2 data for its Zanubrutinib, its treatment candidate for Waldenstrom's macroglobulinemia, at the EHA on Friday.

AbbVie Inc ABBV and Roche Holdings AG Basel ADR Common Stock RHHBY will present Phase 3 data for Venclexta, their relapsed or refractory chronic lymphocytic leukemia, or CLL, treatment candidate, at the EHA on Saturday.

bluebird bio Inc BLUE is due to present Phase 3 data on LentiGlobin, code named HGB-207, from a study called Northstar-2, which evaluated the pipeline candidate for non-beta0/beta0 transfusion-dependent thalassemia, at the EHA on Saturday.

IPOs

Verrica Pharmaceuticals, a clinical-stage dermatology company, is scheduled to IPO, offering 5 million shares at an estimated price range of $14 to $16. The company seeks to list its shares on the Nasdaq under the ticker symbol VRCA.